Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257180 | 1.00 | HTR2C (0.33) | HTR2CDRD2HTR2A | |
| SCHEMBL12846776 | 1.00 | HTR2C (0.33) | HTR2CDRD2HTR2A | |
| SCHEMBL15372185 | 1.00 | HTR2C (0.33) | HTR2CDRD2HTR2A | |
| SCHEMBL2257173 | 1.00 | HTR2C (0.33) | HTR2CDRD2HTR2A | |
| SCHEMBL12847217 | 1.00 | HTR2C (0.33) | HTR2CDRD2HTR2A | |
| SCHEMBL10441576 | 1.00 | HTR2C (0.33) | HTR2CDRD2HTR2A | |
| SCHEMBL2399979 | 0.81 | HTR2C (0.36) | HTR2CDRD2HTR2A | |
| SCHEMBL1922162 | 0.81 | HTR2C (0.36) | HTR2CDRD2HTR2A | |
| SCHEMBL1923837 | 0.81 | HTR2C (0.36) | HTR2CDRD2HTR2A | |
| SCHEMBL2400600 | 0.81 | HTR2C (0.36) | HTR2CDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090922-B2 | Process for the preparation of nebivolol | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2015-07-28 | — | — | US | disclosed |
| US-20130295622-A1 | PROCESS FOR THE PREPARATION OF NEBIVOLOL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2013-11-07 | — | — | US | disclosed |
| EP-2228374-B1 | Nebivolol formate | ZACH SYSTEM SPA (IT) | 2013-06-05 | — | — | EP | disclosed |
| US-8258323-B2 | Process for preparing nebivolol | ZACH SYSTEM S.P.A. (IT) | 2012-09-04 | — | — | US | disclosed |
| WO-2012095707-A1 | PROCESS FOR THE PREPARATION OF NEBIVOLOL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2012-07-19 | — | — | WO | disclosed |
| US-20110201831-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2011-08-18 | — | — | US | disclosed |
| US-7999124-B2 | Process for preparing nebivolol | ZACH SYSTEM S.P.A. (IT) | 2011-08-16 | — | — | US | disclosed |
| US-7999124-B2 | Process for preparing nebivolol | ZACH SYSTEM S.P.A. (IT) | 2011-08-16 | — | — | US | disclosed |
| EP-2228374-A1 | Nebivolol formate | ZaCh System S.p.A. (IT) | 2010-09-15 | — | — | EP | disclosed |
| EP-2099790-B1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM SPA (IT) | 2010-07-07 | — | — | EP | disclosed |
| US-20100056813-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2010-03-04 | — | — | US | disclosed |
| US-20100056813-A1 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2010-03-04 | — | — | US | disclosed |
| WO-2008064827-A2 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201831-A1 | PROCESS FOR PREPARING NEBIVOLOL | ADRB1, ADRB2, ADRA1B | HTR2C 1138/4885DRD2 47/4885HTR2A 1775/4885 |
| US-20100056813-A1 | PROCESS FOR PREPARING NEBIVOLOL | ADRB1, ADRB2, ADRA1B | HTR2C 1138/4885DRD2 47/4885HTR2A 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.